QCG
NRIX icon

Quadrant Capital Group’s Nurix Therapeutics NRIX Stock Holding History

Quadrant Capital Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-344
Closed -$5.33K – 2112
2026
Q1 		$5.33K Buy
344
+278
+421% +$4.61K ﹤0.01% 2338
2025
Q4 		$1.25K Hold
66
– – ﹤0.01% 2577
2025
Q3 		$610 Buy
+66
New +$685 ﹤0.01% 2594
2025
Q2 		– Sell
-66
Closed -$785 – 2159
2025
Q1 		$785 Hold
66
– – ﹤0.01% 2608
2024
Q4 		$1.24K Hold
66
– – ﹤0.01% 2562
2024
Q3 		$1.48K Hold
66
– – ﹤0.01% 2538
2024
Q2 		$1.38K Hold
66
– – ﹤0.01% 2527
2024
Q1 		$971 Hold
66
– – ﹤0.01% 2590
2023
Q4 		$682 Sell
66
-49
-43% -$336 ﹤0.01% 2591
2023
Q3 		$904 Sell
115
-1,367
-92% -$12.5K ﹤0.01% 2498
2023
Q2 		$14.8K Hold
1,482
– – ﹤0.01% 1859
2023
Q1 		$13.2K Buy
+1,482
New +$15.4K ﹤0.01% 1903

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Quadrant Capital Group's NRIX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 344 shares — an estimated $5.33K sold.

Quadrant Capital Group first reported a position in NRIX in Q1 2023 and held it in 12 quarters. The position peaked at $14.8K in Q2 2023. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 344 Nurix Therapeutics shares in Q2 2026, an estimated $5.33K.
  • Quadrant Capital Group first reported a position in Nurix Therapeutics in Q1 2023 and held it in 12 quarters.
  • Quadrant Capital Group's Nurix Therapeutics position peaked at $14.8K in Q2 2023.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.